Budget impact analysis of sarilumab for the treatment of rheumatoid arthritis in patients with an inadequate response to conventional synthetic DMARD or TNF inhibitor therapies

OBJECTIVE: To estimate the 5-year budget impact (BI) on a US health plan of introducing sarilumab – a human immunoglobulin G1 anti-IL-6 receptor α monoclonal antibody – as combination treatment with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) or monotherapy in patients wi...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Clinicoecon Outcomes Res
Autores principales: Ferrufino, Cheryl P, Munakata, Julie, Wei, Wenhui, Proudfoot, Clare, Kuznik, Andreas, Boklage, Susan H, Chen, Chieh-I
Formato: Artigo
Lenguaje:Inglês
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6247948/
https://ncbi.nlm.nih.gov/pubmed/30532571
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CEOR.S163829
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares